I am compiling a list and so far only have two good candidates. If anyone has any good suggestion for me to perform DD on let me know!
I am email able on yahoo and hotmail with my current user name. just use your handle in the subject bar.
Always appreciated. I will be working on the great great Grand Kids inheritance : )
Check out Avanir Pharmaceuticals (AVNR). It's approved lead drug Nuedexta is in Ph3 for additional indications that serve larger markets than PBA. PBA is a small market, but the other indications could be very large. The stock is being held down due to Generic lawsuits and short attacks at the moment. There is a very large short position in this stock. If these lawsuits end up in favor of AVNR as everyone expects, the stock will resume an upward trend over the next couple years as it will have over 20 years of growth and patent protection to look forward to. It could very well become a mid-cap during that 2-3 year time frame if not bought out first.
Check out pSivida Corp (PSDV). They have developed a slow release, miniaturized, drug delivery device for ocular and other diseases. They already have approval and sales in Europe and the potential to partner up with a number of pharmaceutical manufacturers who would like to use their delivery system. It has relatively low volatility for a start-up biotech and I think the risk of failure at this point is minimal. Market cap is also under 100m, so there is a lot of upside potential. There are a couple of good PSDV articles on Seeking Alpha.
Here are a few I've owned for a while that may still have a decent amount of upside potential.
Hurco Companies (makes numerically controlled machining stations)
Apco Oil and Gas (does oil and gas exploration and production in Argentina and Columbia)
UFP Technologies (makes molded plastic parts)
Western Digital (makes hard-disc drives and solid-state drives)
I haven't bough stocks in a long time because I haven't found any stocks that I consider to be undervalued aside from a number of stocks that I already own, which are still somewhat undervalued (though not as undervalued as they were when I bought them). Prana's value is, of course, indeterminate at the present time, so it can't be considered an investment. Right now my portfolio is about 25% cash and 75% stocks.
ATHX with its adult-derived, off-the-shelf stem-cell product platform called MultiStem. Two phase II trials, one for Inflammatory Bowel Disease and another for Ischemic Stroke, both, I believe, with results due in Q1 '14. Nine more trials in the pipe. Market cap
Agree with Todd...check out ATHX. Another very intriguing biotech is ARWR. It is involved in RNAi Therapeutics that develop targeted drugs for RNA interference of disease causing genes. Right now they are finishing up a scuccessful Phase 1 study on treatment of chronically infected Hep B virus patients. There are 350 million sufferers of this disease out there, so this companiy's drug if successful has huge potential. The last 2 days have been interesting for the stock.....starting to run.
ZLCS --- I'm in it huge so I am not the most unbiased. I'd wait until the r/s is off the table (huge volitility right now). Science is close to PRAN... or atleast in the same family-- one of the things that got me looking at PRAN when it was mentioned on the ZLCS YMB. The mechinism for PRAN's was also touched on by the CEO of ZLCS during his last conference at R&R a week or two ago. ZLCS is trying Ca and Na ion channel blockers for pain and other indications. Really high risk in ZLCS the P2's for Z160 are make or break imo... no middle ground.